Bayart, J.-L.; Morimont, L.; Closset, M.; Wieërs, G.; Roy, T.; Gerin, V.; Elsen, M.; Eucher, C.; Van Eeckhoudt, S.; Ausselet, N.; David, C.; Mullier, F.; Dogné, J.-M.; Favresse, J.; Douxfils, J. Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of NT162b2. Microorganisms2021, 9, 1340.
Bayart, J.-L.; Morimont, L.; Closset, M.; Wieërs, G.; Roy, T.; Gerin, V.; Elsen, M.; Eucher, C.; Van Eeckhoudt, S.; Ausselet, N.; David, C.; Mullier, F.; Dogné, J.-M.; Favresse, J.; Douxfils, J. Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of NT162b2. Microorganisms 2021, 9, 1340.
Bayart, J.-L.; Morimont, L.; Closset, M.; Wieërs, G.; Roy, T.; Gerin, V.; Elsen, M.; Eucher, C.; Van Eeckhoudt, S.; Ausselet, N.; David, C.; Mullier, F.; Dogné, J.-M.; Favresse, J.; Douxfils, J. Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of NT162b2. Microorganisms2021, 9, 1340.
Bayart, J.-L.; Morimont, L.; Closset, M.; Wieërs, G.; Roy, T.; Gerin, V.; Elsen, M.; Eucher, C.; Van Eeckhoudt, S.; Ausselet, N.; David, C.; Mullier, F.; Dogné, J.-M.; Favresse, J.; Douxfils, J. Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of NT162b2. Microorganisms 2021, 9, 1340.
Abstract
Background: Little is known about potential confounding factors influencing the humoral response in individuals having received the BNT162b2 vaccine. Methods: Blood samples from 231 subjects were collected before and 14, 28 and 42 days following COVID-19 vaccination with BNT162b2. Anti-Spike Receptor-Binding-Domain protein (anti-Spike/RBD) immunoglobulin G (IgG) antibodies were measured at each time-point. Impact of age, sex, childbearing age status, hormonal therapy, blood group, body mass index and past-history of SARS-CoV-2 infection were assessed by multivariable analyses. Results and Conclusions: In naïve subjects, the level of anti-Spike/RBD antibodies gradually increased following administration of the first dose to reach the maximal response at day 28 and then plateauing at day 42. In vaccinated subjects with previous SARS-CoV-2 infection, the plateau was reached sooner (i.e. at day 14). In the naïve population, age had a significant negative impact on anti-Spike/RBD titers at day 14 and 28 while lower levels were observed for males at day 42, when corrected for other confounding factors. BMI as well as B and AB blood groups had a significant impact in various subgroups on the early response at day 14 but no longer after. No significant confounding factors were highlighted in the previously infected group.
Biology and Life Sciences, Biochemistry and Molecular Biology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
*
